Clinical Trials · NCT05896566
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Enrollment
- 231
- Start date
- Jan 2024
- Locations
- 37 sites, 6 countries
- Primary endpoint
- Change in Ki 67